Drug developer files patents for cancer treatment which ‘outperforms’ AstraZeneca offering December 20, 2022 Drug development company Nuformix has reformulated and improved one of AstraZeneca’s top cancer drugs, piquing investor interest today. Shares in the London-listed firm jumped nearly a quarter to 35p per share by early afternoon on Tuesday. Nuformix, which focuses on fibrosis and cancer drug repurposing, announced that the drug, known as Olaparib, had “outperformed” AstraZeneca’s [...]
European regulator injects hope into AstraZeneca’s bid to tackle cancer December 19, 2022 The European Medicines Agency has handed AstraZeneca a number of recommendations and one approval for a trio of cancer drugs the Big Pharma firm is looking to market in the continent. AstraZeneca’s cancer drug Enhertu has been given the green light by the European regulator for use among patients with gastric cancer. Around 136,000 cases [...]
AstraZeneca buys therapy firm Neogene for £266m in latest bid to tackle cancer November 29, 2022 AstraZeneca has bought cancer cell therapy company Neogene Therapeutics for $320m (£266m), in the company’s latest investment in its oncology offering. The deal, which is set to close in the coming months, will see AstraZeneca pay $200m as cash in hand, and another $120m if Neogene meets certain milestones. The British-Swedish pharmaceutical giant, behind one [...]
Drug developer C4X shares fly after signing £330m AstraZeneca licensing deal November 28, 2022 Drug developer C4X Discovery has signed an exclusive licensing agreement worth up to $402m (£334m) with pharma giant AstraZeneca to develop oral therapy to treat inflammatory diseases. London-listed C4XD’s shares have rocketed this morning, up nearly 40 per cent to 28.5p so far. As part of the deal, C4XD will receive pre-clinical milestone payments worth up [...]
AstraZeneca’s battle against cancer knocks on door of EU with three new drugs November 14, 2022 AstraZeneca, the pharmaceutical giant behind one of the world’s first Covid-19 vaccines, has had three new cancer drugs recommended for approval in the European Union. The FTSE 100 pharma firm said its drug Imfinzi – for uses against biliary tract cancer alongside chemotherapy, gastric cancer medicine Enhertu and prostate cancer treatment Lynparza, in combination with [...]
AstraZeneca boss urges UK government to invest in medicines of the future November 10, 2022 The chief of AstraZeneca has urged the UK government to invest in the medicines of the future, as the regulatory environment for pharma in the US grows tougher. With the UK’s upcoming budget, CEO Pascal Soriot called on the government to protect the funding for innovative treatments as the long-term outlook for the healthcare industry [...]
Investors bet on AstraZeneca’s experimental breast cancer drug following positive trial October 26, 2022 Shares rose in AstraZeneca today on the back of progress made with its breast cancer treatment, which combines its older Faslodex drug with a new experimental offering. Breast cancer is the most common cancer in the world, with around 2.3 million patients diagnosed with the disease in 2020. It follows a disappointing result in a [...]
AstraZeneca asthma drug misses key marker in late-stage trial October 25, 2022 AstraZeneca’s asthma drug failed to significantly improve difficulties swallowing in a late-stage trial, the pharmaceutical giant announced today. The drug, called Fasenra, met just one of two main goals of a stage III study assessing the treatment’s benefits in a chronic allergic condition that causes difficulty in swallowing. The condition, eosinophilic esophagitis, is characterised by [...]
Drop in Covid-19 vaccine demand swings Oxford Biomedica to a loss September 15, 2022 A drop in Covid-19 vaccine demand and manufacturing has swung British biotech firm Oxford Biomedica to a revenue loss in the half of the year. The London-listed firm, which worked with AstraZeneca’s to produce its Covid-19 vaccine, has revenue slip more than 20 per cent to £64m in the six moths to 30 June, down [...]
AstraZeneca share price dips with investors ‘underwhelmed’ by diabetes drug August 30, 2022 AstraZeneca’s share price has dipped into the red today, with investors “underwhelmed” by its diabetes and heart failure drug Fraxiga. The stock sank 1.8 per cent to 11,160p per share by early afternoon. However, the share price has grown 6.2 per cent over the past three months. ‘’Investors appear to have been underwhelmed by the [...]